[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microvascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microvascular-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,77,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643002","collecting-data-on-retinal-blood-blood-flow-and-blood-vessel-shapeappearance-using-an-investigational-device-xycam-cre-and-to-then-compare-those-images-with-images-collected-from-a-patients-routine-clinical-examination-100643002",false,"NCT07641738","Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape\u002FAppearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.","Evaluation of Patients With Retinal Disorders Utilizing the XyCAM CRE Camera.","Inclusion Criteria:\n\n* The Subject present to the ophthalmology\u002Foptometry clinic for eye examination. A signed\u002Fdated consent form has been obtained from a Subject who is capable of giving informed consent and compliant with the restrictions and requirements if the protocol.\n\nThe Subject is 21 years old with binocular vision.\n\nExclusion Criteria:\n\n* The Subject has significant media opacity (eg: a significant corneal scar) The Subject's medical history or health status suggests that the Subject may have an adverse reaction to administration of tropicamide or fluorescein dye.\n\nThe Subject has more than 15 dioptors of refractive error. The Subject is less that 21 years of age. The Subject is unable to follow instructions or otherwise unable to complete the study procedures.\n\nThe Subject has medical conditions such as nystagmus that will likely prevent the Subject from being able to hold their gaze steady during imaging, reducing the likelihood that high quality data can be acquired from the Subject.\n\nThe Subject is pregnant.",true,"ALL","21 Years","100 Years",{"count":21,"type":22},350,"ESTIMATED","OBSERVATIONAL","The primary objective of the XyCAM CRE Camera Study is to evaluate retinal blood flow, choroidal blood flow, and retinal structural features and their association with the progression and characterization of retinal diseases using the XyCAM CRE Camera. The XyCAM CRE is an investigational, noninvasive optical imaging instrument manufactured by Vasoptic Medical, Inc.\n\nXyCAM CRE imaging data will be collected and compared with established retinal imaging modalities currently used in ophthalmic clinical practice, including Color Fundus Photography (CFP), Optical Coherence Tomography (OCT), Optical Coherence Tomography Angiography (OCTA), and Fluorescein Angiography (FA). Imaging data obtained from XyCAM CRE and reference modalities will be assessed to investigate correlations, agreement, and differences between measurements in order to evaluate the potential of XyCAM CRE to provide complementary diagnostic and disease management information in retinal disease.\n\nSecondary objectives of the study include:\n\nComparing image quality and image-derived information obtained from XyCAM CRE with other clinical reference imaging modalities across different operators and a diverse study population representative of the general population; Investigating the relationship between XyCAM CRE imaging data and established clinical indicators of glaucoma, macular degeneration, hypertensive retinopathy, diabetic retinopathy, inherited retinal disease, and retinal vascular disease.",[26,27],"Microvascular Disease","Retinal Disease",[29,30],"XyCAM CRE","XyCAM RI","NOT_YET_RECRUITING","2026-06-06",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":22},"2026-06-15",{"date":39,"type":22},"2030-06-15",{"name":41,"class":42},"Stuart Terry Eye Associates","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":43},"100564061","test-of-reproducibility-of-15oh20-pet-assessment-of-brain-perfusion-100564061","NCT06624267","Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion","Small Vessel Disease of the Brain and Heart: a Perfusion PET Study of Training Effects","SVAT","Inclusion Criteria:\n\n* Age \\> 60 years\n* No diagnosis of T2D according to WHO\\'s criteria.\n* Speaks and understands Danish (required for reliable cognitive testing)\n* Able to provide informed and written consent\n\nExclusion Criteria:\n\n* Moderate to high intensity training \\>2 times\u002Fweek.\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.","60 Years",{"count":54,"type":22},8,"In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.\n\nIt has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.\n\nAmong other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.\n\nExercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions.\n\nSystemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max).",[26,57,58,59,60],"Microvascular Complications","Diabetes Mellitus Type 2","Cerebral Hypoperfusion","Dementia",[62,63,64,65,66,67],"microvascular disease","microvascular complications of the heart","microvascular complications of the brain","microvascular disease patophysiology","diabetes type 2","dementia","2024-10-02",{"date":70,"type":35},"2024-10-04",{"date":72,"type":22},"2024-11",{"date":74,"type":22},"2027-12",{"name":76,"class":42},"University Hospital Bispebjerg and Frederiksberg",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":50,"eligibilityCriteria":83,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":55,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":43},"100564370","comparison-of-differencens-in-vo2-max-perfusion-of-the-heart-and-brain-and-cognitive-performance-between-patients-with-type-2-diabetes-and-healthy-age-matched-controls-100564370","NCT06628297","Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.","Small Vessel Disease of the Brain and Heart a PET Perfusion Study of Training Effects","Inclusion Criteria for the patients with type 2 diabetes:\n\nDiabetes type II diagnose with one of the following:\n\n* Duration over 5 years\n* Moderate microalbuminuria\n* Non-proliferative diabetic retinopathy\n\n  * Speaks and understands Danish (required for reliable cognitive testing)\n  * Able to provide informed and written consent\n\nExclusion Criteria or the patients with type 2 diabetes:\n\nModerate to high intensity training \\>1 times\u002Fweek.\n\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.\n\nInclusion Criteria for the healthy age-matched controls:\n\n* Age \\> 60 years\n* No diagnosis of T2D according to WHO\\'s criteria.\n* Speaks and understands Danish (required for reliable cognitive testing)\n* Able to provide informed and written consent\n\nExclusion Criteria for the healthy age-matched controls:\n\n* Moderate to high intensity training \\>2 times\u002Fweek.\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.",{"count":85,"type":22},72,[26,57,60,58,59],[62,63,64,66,67,65],{"date":70,"type":35},{"date":72,"type":22},{"date":74,"type":22},{"name":76,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":104,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":43},"100409502","micro-a-registry-study-in-patients-with-microvascular-angina-100409502","NCT04612322","MICRO: a Registry Study in Patients With Microvascular Angina","A Multicenter Registry on the Diagnosis of Patients With Chronic Angina and no Angiographic Coronary Artery Stenosis","MICRO","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C85 years.\n* Chronic coronary syndrome (including patients with anginal equivalents)\n* Angina CCS class II-IV\n* Evidence of reversible ischemia on non-invasive testing\n* Availability of the following measurements:\n\n  1. Index of microvascular resistances (IMR),\n  2. Resting full-cycle ratio (RFR),\n  3. Fractional flow reserve (FFR),\n  4. Coronary flow reserve (CFR)\n* Willingness to participate and ability to understand read and signed the informed consent document before the procedure\n\nExclusion Criteria:\n\nAt least one of the following:\n\n* Pregnancy and or lactation.\n* Medical or psychological conditions that would jeopardize an adequate and orderly participation.\n* Left ventricular ejection fraction lower than 30%\n* Previous coronary artery bypass surgery (CABG) to all major branches in the LAD and left circumflex (LCX) territory, such that IMR cannot be measured\n* Decompensated congestive heart failure (CHF)\n* Chronic or acute renal failure with creatinine \\>2mg\u002Fdl\n* Severe valvular heart disease\n* Patients with comorbidities limiting life expectancy to less than one year","18 Years","85 Years",{"count":103,"type":22},1000,"5 Years","The evidence above demonstrates that microvascular dysfunction is an important determinant of patient prognosis, which however remains poorly classified. Given the high burden of disease and the severity of the functional impairment in these patients, the lack of a clear definition for this disease has a potentially large clinical importance. It is important to better describe the phenotype of these patients, identify the predictors of prognosis, and determine the impact of diagnosis.",[26],[108,109],"Coronary artery disease","Angina","RECRUITING","2022-03-29",{"date":113,"type":35},"2022-03-31",{"date":115,"type":35},"2020-10-10",{"date":117,"type":22},"2029-10-10",{"name":119,"class":42},"Johannes Gutenberg University Mainz"]